Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon FTE services & FFS services - flexible and efficient cooperation model| Medicilon appeared at the 25th SAPA-NE Annual Conference
Feb 21,2024
Medicilon won the "Best Strategic Partner" award from NewDEL Biotech in 2023
Shanghai Medicilon Inc. (Medicilon) has recently won the "Best Partner Award" from Gluetacs Therapeutics and the "2003 Best Partner Award" from SicaGene.
More
Medicilon won the "Best Strategic Partner" award from NewDEL Biotech in 2023
Jan 30,2024
Medicilon was selected as the "2023 Shanghai Professional Technical Service Platform"
On January 18, the Science and Technology Commission of Shanghai Municipality released the 2023 Shanghai Professional Technical Service Platform construction project list. There are only 29 platforms in Shanghai on the list. Medicilon Preclinical Research (Shanghai) LLC, a subsidiary of Shanghai Medicilon Inc. (Medicilon), Nucleic Acid Drug R&D Service Platform was successfully selected!
More
Medicilon was selected as the "2023 Shanghai Professional Technical Service Platform"
Jan 30,2024
Gain Client Recognition Again! Medicilon won the 2023 SicaGene "Best Partner Award"
Recently, Shanghai Medicilon Inc. (Medicilon) won the "Best Partner Award" from SicaGene. The strong support provided in collaboration projects has been recognized by client again.
More
Gain Client Recognition Again! Medicilon won the 2023 SicaGene "Best Partner Award"
Jan 22,2024
Empowering two pipelines with dual reporting and batching in China and the United States - Medicilon won the "2023 Best Partner Award" from Gluetacs Therapeutics
On January 8, Dr. Xiaobao Yang, Chairman and CEO of Gluetacs Therapeutics (Gluetacs) awarded Shanghai Medicilon Inc. (Medicilon) the "2023 Best Partner Award”. Dr. Jinna Cai, Chief Commercial Officer of Medicilon, and Bolin Zhang, Director of CMC of Key Account Development Department, attended the award ceremony.
More
Empowering two pipelines with dual reporting and batching in China and the United States - Medicilon won the "2023 Best Partner Award" from Gluetacs Therapeutics
Jan 08,2024
Medicilon Summary for 2023
As an enabler of the pharmaceutical industry, Medicilon adheres to its original mission, works hard and moves forward resolutely, writing Medicilon's "answer"for 2023!
More
Medicilon Summary for 2023
Jan 05,2024
Three years in a row! Medicilon once again appears on the 2023 "Influential Preclinical CRO Enterprises of the Year" list
On December 15, the 4th China Biopharmaceutical Industry Chain Innovation and Transformation Summit and the 4th China Biopharmaceutical Innovation Billboard Awards Ceremony were grandly held in Hangzhou. This is the third consecutive year that Medicilon has won this award!
More
Three years in a row!  Medicilon once again appears on the 2023 "Influential Preclinical CRO Enterprises of the Year" list
Jan 05,2024
Medicilon signed a strategic collaboration agreement with the North American 100 Angel Investment
On December 22, 2023, Medicilon and North America 100 Angel Investment LLC announced that the two parties had officially signed a strategic collaboration agreement in Boston. This collaboration will bring huge opportunities to both parties and promote the global development of both parties in the field of innovative drug research and development.
More
Medicilon signed a strategic collaboration agreement with the North American 100 Angel Investment
Jan 04,2024
Medicilon appoints Dr. Zhang Haizhou as President of Preclinical R&D Unit
Recently, Medicilon appoints Dr. Zhang Haizhou as President of Preclinical R&D Unit. Dr. Zhang Haizhou holds a PhD in Toxicology from Indiana University, USA. He is a pharmaceutical industry veteran with over 20 years of experience in the R&D of small and large molecule drugs.
More
Medicilon appoints Dr. Zhang Haizhou as President of Preclinical R&D Unit
Dec 29,2023
Medicilon Interview with Dr. Wenbo Zhou | Focusing on difficult-to-drug targets, three INDs have been approved in three years. What are the advantages of Yuyao Biotech?
Medicilon conducted an exclusive interview with Dr. Wenbo Zhou, the founder of Yuyao Biotech. The clinical trial of YY201, the world's first STAT3 small molecule inhibitor by Yuyao Biotech, has been officially approved by the US FDA.
More
Medicilon Interview with Dr. Wenbo Zhou | Focusing on difficult-to-drug targets, three INDs have been approved in three years. What are the advantages of Yuyao Biotech?
Dec 29,2023
Medicilon Interview with Dr. Yifan Zhan | CD73 targeted therapy has ushered in a new dawn, revealing the research history and future prospects of Huaota Biopharmaceutical
In the field of immunotherapy, CD73, an immune regulatory molecule, has attracted much attention in recent years. Medicilon had the honor to interview Dr. Yifan Zhan, Chief Scientist of Huaota.
More
Medicilon Interview with Dr. Yifan Zhan | CD73 targeted therapy has ushered in a new dawn, revealing the research history and future prospects of Huaota Biopharmaceutical
Dec 28,2023
Medicilon was awarded the "Industry Outstanding Member Unit Management Award" by the China Laboratory Primate Breeding and Development Association
Recently, the China Laboratory Primate Breeding and Development Association Industry Academic Exchange Conference and 30th Anniversary Celebration were held as scheduled at the Dragon Lake Princess Hotel in Huadu, Guangzhou. As a member, Shanghai Medicilon Inc. was invited to attend the conference and was awarded the "Industry Outstanding Member Unit Management Award".
More
Medicilon was awarded the "Industry Outstanding Member Unit Management Award" by the China Laboratory Primate Breeding and Development Association
Dec 22,2023
Pharmalego intermediates e-commerce platform launched; We have what scientific researchers are struggling to find
From a one-stop biopharmaceutical preclinical R&D service platform, to Medicilon Academician Innovative Drug Maturation Center and New Drug Ecological Assistance Platform, to building a pharmaceutical network (PharmalegoTM), Medicilon is willing to help you overcome the obstacles on the journey of new drug research and development.
More
Pharmalego intermediates e-commerce platform launched; We have what scientific researchers are struggling to find